How AI is Transforming Drug Discovery
Dotmatics executives Kalim Saliba and Steve Tharp explain in an NBC News Boston feature how AI is revolutionizing drug discovery by enabling researchers to navigate complex data more efficiently, significantly reducing development time and costs, and accelerating the creation of safer, personalized medicines.
In this NBC News Boston feature, Dotmatics executives, Kalim Saliba and Steve Tharp, discuss how artificial intelligence is transforming drug discovery and the broader healthcare industry. Bringing a new drug to market can take more than a decade and cost billions, but AI is helping researchers cut through data complexity, accelerate timelines, and improve outcomes.
Dotmatics is leading this race to AI—empowering scientists with tools that act like “a thousand lab researchers at their side.” The result: faster, more cost-effective development of life-saving therapeutics, and a future where patients gain access to safer, more personalized medicines in years instead of decades.
Watch the full interview to hear Dotmatics leaders share their perspective on how AI is reshaping the future of medicine.
Related
Gray TV Washington DC: AI helping scientists make drug breakthroughs
The Gray TV Washington DC feature highlights how scientists, including Christian Olsen of Dotmatics, are leveraging AI and machine learning to accelerate drug discovery and expedite bringing new drugs to market.
NBC Las Vegas: AI is Accelerating Drug Discovery and Vaccine Development
In an NBC Las Vegas interview, Phil Mounteney, VP of Science and Technology at Dotmatics, explains how AI is transforming drug discovery and vaccine development by accelerating research timelines, reducing costs, enhancing drug safety through advanced data analysis, and optimizing development pipelines for faster and more efficient medical breakthroughs post-COVID.
The Future of AI in Drug Discovery
The Forbes article discusses how AI is revolutionizing drug discovery by accelerating R&D and improving decision-making, highlighting Dotmatics’ role in integrating data and applying AI to scientific workflows, while also connecting these advancements to broader innovations in sustainability and global problem-solving.
NBC News: How AI is Transforming Drug Discovery
In an NBC News segment, Alister Campbell, VP of Dotmatics, explains how the company leverages AI to analyze large datasets, predict effective drug compounds, and streamline fragmented data systems and manual workflows, thereby accelerating and improving the efficiency of drug discovery.
KRON TV: AI in Medicine From Research Assistant to Predictive Partner
In a KRON-TV interview, Dotmatics VP Phil Mounteney discusses how AI is evolving from a research assistant automating data tasks to a predictive partner that accelerates drug discovery by identifying new targets, designing molecules, and enabling personalized therapies, ultimately reducing costs and time to market while expanding patient access to safer, tailored medicines.
NBC Louisiana: How AI is Accelerating Drug Discovery
In an NBC Louisiana feature, Dotmatics’ VP Phil Mounteney explained how AI is revolutionizing drug discovery by significantly reducing development time from up to ten years to potentially half, enhancing efficiency in analyzing vast data sets while ensuring data privacy by keeping sensitive information secure and in-house.